注意力不足過動症 (ADHD) 治療市場：按藥物類型、年齡層、分銷管道和地區分類

Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, By Age Group, by Distribution Channel, By Geography

出版日期: 2026年02月05日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，注意力不足過動症（ADHD）治療市場規模預計為265.57億美元，預計到2033年將達到429.43億美元。預計2026年至2033年，該市場將以7.1%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	265.57億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.10%	2033年市場規模預測：	429.43億美元

全球注意力不足過動症（ADHD）藥物市場涵蓋了用於治療ADHD的各種藥物。這些藥物包括多種類型，例如興奮劑類藥物，如安非他命、哌甲酯、菲達起司安非他明、右旋哌甲酯和安非他命二甲磺酸鹽，以及非興奮劑類藥物，如阿托莫西汀、安非他酮、胍法辛和可樂定。 ADHD分為三種：注意力不集中型、過動衝動型和混合型。 ADHD的原因包括腦損傷、懷孕飲酒和吸菸、早產和低出生體重。這是一種慢性疾病，影響著數百萬兒童，並且常常持續到成年。患有ADHD的兒童常常面臨自卑和學業成績不佳的問題。雖然ADHD無法治愈，但其症狀可以控制。 ADHD的治療方法包括藥物治療和行為療法。 ADHD的主要症狀是注意力不集中。人們認為 ADHD 是由多種因素共同作用導致的，包括遺傳因素。研究人員正在調查可能增加 ADHD 疾病風險的環境因素，以及腦損傷、營養和社會環境在 ADHD 中所扮演的角色。

市場動態

主要企業正致力於技術創新，以鞏固其在全球注意力不足過動症（ADHD）治療市場的地位。例如，2020年6月，數位處方藥公司Akili Interactive Labs的處方藥EndeavorRx™（AKL-T01）獲得美國食品藥物管理局（FDA）核准，用於治療和改善ADHD患兒的注意力。

本報告的主要特點

本報告對全球注意力不足/過動症 (ADHD) 治療市場進行了詳細分析，包括市場規模和預測期 (2026-2033) 的複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球注意力不足/過動症 (ADHD) 治療市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球注意力不足過動症 (ADHD) 治療市場》報告面向該行業的眾多相關人員，包括經銷商、供應商、產品製造商、分銷商、新進業者和金融分析師。
相關人員可以透過分析全球注意力不足/過動症 (ADHD) 治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Amnel Pharmaceuticals LLC.
Eli Lilly And Company
Johnson &Johnson Services, Inc.
Noven Pharmaceuticals, Inc.
RespireRx Pharmaceuticals Inc.
Otsuka Pharmaceutical Co., Ltd.
Neos Therapeutics, Inc.
American Brivision（Holding）Corporation
Novartis AG
Takeda Pharmaceutical Company Limited
GSK plc
Purdue Pharma LP
Cingulate
Adlon Therapeutics LP
Tris Pharma, Inc.
Neuraxpharm
Supernus Pharmaceuticals, Inc.
Aytu Biopharma, Inc.

第9章

分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI830

Attention Deficit Hyperactivity Disorder Treatment Market is estimated to be valued at USD 26,557 Mn in 2026 and is expected to reach USD 42,943 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 26,557 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.10%	2033 Value Projection:	USD 42,943 Mn

The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD.

Market Dynamics

Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD.

Key features of the study

This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market

Market Segmentation

Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine Dimesylate
- Non-stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
Age Group Insights (Revenue, USD Mn, 2026 - 2033)
- Pediatric and Adolescent
- Adult
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Amnel Pharmaceuticals LLC.
- Eli Lilly And Company
- Johnson & Johnson Services, Inc.
- Noven Pharmaceuticals, Inc
- RespireRx Pharmaceuticals Inc
- Otsuka Pharmaceutical Co. Ltd
- Neos Therapeutics, Inc.
- American Brivision (Holding) Corporation
- Novartis AG
- Takeda Pharmaceutical Company Limited
- GSK plc
- Purdue Pharma L.P.Cingulate
- Adlon Therapeutics L.P.
- Tris Pharma, Inc.
- Neuraxpharm
- Supernus Pharmaceuticals, Inc.
- Aytu Biopharma, Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Regulatory Scenario
Pricing Analysis
Brand Mapping
Pipeline Analysis
PEST Analysis

4. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Stimulants
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
  - Amphetamine
  - Methylphenidate
  - Dextroamphetamine
  - Dexmethylphenidate
  - Lisdexamfetamine Dimesylate
Non-Stimulants
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
  - Atomoxetine
  - Bupropion
  - Guanfacine
  - Clonidine

5. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pediatric and Adolescent
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adult
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Amnel Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly And Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Noven Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
RespireRx Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Neos Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
American Brivision (Holding) Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Purdue Pharma L.P.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cingulate
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Adlon Therapeutics L.P.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Tris Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Neuraxpharm
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Supernus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Aytu Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies